Alkermes PLC is betting that the novel design of its Phase III clinical trials, including the recently positive FORWARD-5 trial and two previously failed studied, and its overall data package will be enough to convince the FDA to approve its depression drug ALKS 5461 – a risky approach in a tough indication.
The company’s first two Phase III trials (FORWARD-3 and FORWARD-4) did not show a significant benefit versus placebo as an...






